ClinicalTrials.Veeva

Menu
H

Hospital Quironsalud Barcelona | Internal Medicine Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

INCB099280
Pembrolizumab
Plozasiran
Leucovorin
Triglycerides
Tesetaxel
Latanoprost
Netarsudil
5-fluorouracil
Pemafibrate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 22 total trials

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

The purpose of this study is to evaluate the safety and tolerability of INCB099280 in combination with adagrasib and to establish the MTD or identify...

Active, not recruiting
Advanced Solid Tumors
Drug: adagrasib
Drug: INCB099280

This study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity...

Active, not recruiting
Advanced Solid Tumors
Drug: axitinib
Drug: INCB099280

The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).

Enrolling
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Drug: ABP 234
Drug: Pembrolizumab (EU)

This study will compare DS 8201a to standard treatment.Participants must have HER2 breast cancer that has been treated before.Their cancer:* cannot b...

Active, not recruiting
Breast Cancer
Drug: Trastuzumab
Drug: Trastuzumab deruxtecan

A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 (Mevrometostat) in Adult Patients With Relapsed/Refractory Small Cell Lung Cancer...

Enrolling
Follicular Lymphoma (FL)
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Drug: Enzalutamide
Drug: Mervometostat (PF-06821497)

The primary objective of this study is to demonstrate pharmacokinetic (PK) similarity ABP 234 with pembrolizumab.

Enrolling
Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
Drug: ABP 234
Drug: Pembrolizumab

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). A...

Enrolling
Hypertriglyceridemia
Drug: Placebo
Drug: Plozasiran Injection

This is a multicenter, open-label, single-arm study to investigate the safety, tolerability, PK, pharmacodynamics and preliminary activity of INCA324...

Active, not recruiting
Advanced Malignancies
Drug: INCA32459-101

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (...

Enrolling
Severe Hypertriglyceridemia
Drug: Plozasiran Injection
Drug: Placebo

The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of...

Enrolling
Non Small Cell Lung Cancer
Drug: Taletrectinib

This study will compare DS-8201a to physician choice standard treatment.Participants must have HER2-low breast cancer that has been treated before.Pa...

Active, not recruiting
Breast Cancer
Drug: Eribulin
Drug: Nab-paclitaxel

Trial sponsors

Incyte logo
Amgen logo
Arrowhead Pharmaceuticals logo
Daiichi Sankyo logo
Aerie Pharmaceuticals logo
BioNTech logo
Gilead Sciences logo
H
Ipsen logo
K

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems